Microrna (mirna) Market Size 2026-2030
The microrna (mirna) market size is valued to increase by USD 4.21 billion, at a CAGR of 22.3% from 2025 to 2030. Increasing incidence of cancer and the imperative for advanced diagnostics and therapeutics will drive the microrna (mirna) market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 45.7% growth during the forecast period.
- By Type - Consumables segment was valued at USD 1.21 billion in 2024
- By End-user - Academic and government research segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 5.55 billion
- Market Future Opportunities: USD 4.21 billion
- CAGR from 2025 to 2030 : 22.3%
Market Summary
- The microRNA (miRNA) market is defined by its critical role in advancing precision medicine through innovative applications in diagnostics and therapeutics. Core drivers include the increasing need for non-invasive circulating mirna biomarkers for early disease detection and the technological progress in next-generation sequencing (ngs) and qrt-pcr quantification.
- A key trend is the development of therapeutic mirna mimics and anti-mirna oligonucleotides (amos), which target gene expression regulation at the post-transcriptional gene silencing level. However, the industry faces challenges in clinical assay development and standardization, which can impact the biomarker validation process.
- For instance, a biotechnology firm developing a novel liquid biopsy development platform must navigate complex regulatory pathways, ensuring that its bioinformatics data analysis and preanalytical variable control meet stringent requirements. This involves extensive validation of the disease signature identification capabilities to prove clinical utility.
- The convergence of exosomal mirna analysis and multi-omics data integration is creating new avenues, positioning mirna-based diagnostics and oncogene regulation strategies at the forefront of medical innovation, from molecular subtyping to new drug discovery pipelines.
What will be the Size of the Microrna (mirna) Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Microrna (mirna) Market Segmented?
The microrna (mirna) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Type
- Consumables
- Instruments
- End-user
- Academic and government research
- Biotechnology and pharmaceutical companies
- CROs and clinical diagnostic centers
- Application
- Cancer
- Infectious diseases
- Cardiovascular diseases
- Immunological disorders
- Others
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Asia
- Rest of World (ROW)
- North America
By Type Insights
The consumables segment is estimated to witness significant growth during the forecast period.
The consumables segment is foundational to the Microrna (mirna) Market, driven by the recurring need for essential products in the drug discovery pipeline and clinical assay development.
This category encompasses a broad range of items, including mirna isolation kits and reagents for qrt-pcr quantification, which are vital for transcriptomics research. The high volume of high-throughput screening assays in academic and commercial labs ensures a consistent demand.
As molecular pathology systems advance, so does the requirement for precise small rna library preparation.
The pursuit of real-world evidence generation and positive health economic outcome research further solidifies the segment’s importance, though success hinges on robust preanalytical variable control and diagnostic assay standardization, with some new multi-analyte tests achieving 95% specificity in distinguishing disease states.
The Consumables segment was valued at USD 1.21 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 45.7% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Microrna (mirna) Market Demand is Rising in North America Request Free Sample
The geographic landscape of the Microrna (mirna) Market is led by North America, which benefits from substantial R&D funding and a mature biotechnology sector focused on mirna expression profiling.
However, Asia is the fastest-growing region, with a growth rate over 23%, driven by government investments in healthcare and life sciences. The region's focus on host-pathogen interaction studies and metabolic disease regulation is fueling demand for next-generation sequencing (ngs) technologies.
Europe maintains a strong position through collaborative research on non-coding rna analysis and gene expression regulation, particularly in developing therapeutic mirna mimics and anti-murine oligonucleotides (amos).
In North America, the implementation of standardized functional genomics screening protocols has reduced inter-laboratory variability by 15%.
This diverse global activity in areas like immune response modulation and fibrosis biomarker research highlights the expanding applications and regional opportunities within the market.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The strategic direction of the global microrna (mirna) market 2026-2030 is increasingly shaped by detailed technical evaluations and application-specific demands. A central debate involves comparing qpcr vs ngs for mirna quantification, with next-generation sequencing platforms for small rna sequencing offering comprehensive discovery capabilities, while qPCR provides targeted, cost-effective validation.
- The development of mirna profiling for cancer early detection remains a primary focus, where liquid biopsy tests using exosomal mirnas are demonstrating significant promise. In therapeutics, the progression of anti-mirna oligonucleotides in clinical trials represents a major milestone, although significant challenges in mirna therapeutic delivery persist.
- The use of mirna mimics for restoring tumor suppressor function is another critical research area. Integrating mirna data with other omics layers is essential for elucidating complex disease pathways, especially for understanding the role of mirna in neurodegenerative disease progression and developing mirna signatures for autoimmune diseases.
- Firms leveraging machine learning for mirna biomarker discovery report specificity improvements nearly double those of traditional statistical methods, underscoring the importance of advanced bioinformatics tools for mirna target prediction.
- Success hinges on addressing the standardization of circulating mirna protocols, the use of mirnas as predictive treatment biomarkers, and navigating the regulatory pathways for mirna-based diagnostics to ensure the validation of mirna signatures in clinical cohorts.
What are the key market drivers leading to the rise in the adoption of Microrna (mirna) Industry?
- The rising global incidence of cancer and the urgent need for more advanced, non-invasive diagnostics and therapeutics serve as a primary driver for the market.
- Market expansion is primarily driven by the urgent clinical need for improved, non-invasive diagnostic tools. The rising incidence of cancer fuels demand for circulating mirna biomarkers and advanced mirna-based diagnostics that can facilitate early disease signature identification.
- This is particularly critical for oncogene regulation and tracking tumor suppressor mirna activity. The utility of these biomarkers extends to prognostic biomarker discovery, where they can predict disease course with over 85% accuracy in certain cancers.
- In addition, the development of predictive biomarker development guides personalized treatment strategies, enhancing the efficacy of companion diagnostic development.
- This demand is not limited to oncology; cardiovascular disease biomarkers and neurodegenerative disease markers are also significant growth areas, where early and accurate treatment response monitoring can dramatically improve patient outcomes.
What are the market trends shaping the Microrna (mirna) Industry?
- A key market trend involves the integration of microRNA profiling into multi-analyte liquid biopsy platforms. This approach enhances early cancer detection by combining insights from multiple biomarker classes.
- Key trends in the Microrna (mirna) Market center on the strategic integration of advanced technologies to enhance diagnostic precision. The shift toward liquid biopsy development is accelerating, with a strong focus on multi-cancer early detection (mced).
- These platforms leverage sophisticated bioinformatics data analysis and machine learning for mirna biomarker discovery to perform complex tasks like tissue of origin testing and molecular subtyping, improving detection accuracy by up to 25% compared to single-marker assays. The incorporation of single-cell mirna analysis and pathway analysis tools is providing deeper insights into disease heterogeneity.
- Furthermore, the trend of multi-omics data integration, which combines miRNA profiles with proteomic biomarker integration, is enabling more comprehensive patient risk stratification, leading to better-informed decisions in precision oncology applications.
What challenges does the Microrna (mirna) Industry face during its growth?
- A significant challenge affecting industry growth is the persistent lack of standardization and technical reproducibility in microRNA analysis across different platforms and laboratories.
- Significant challenges persist in the Microrna (mirna) Market, primarily concerning technical consistency and therapeutic application. The lack of standardized data normalization methods leads to considerable inter-lab variability, with some studies showing discrepancies in quantification results as high as 40%. This complicates the biomarker validation process for translational medicine applications.
- In therapeutics, complexities related to antisense oligonucleotide therapy, including delivery via viral vector systems or lipid nanoparticle delivery, remain a major hurdle. Ensuring targeted delivery and avoiding off-target effects during post-transcriptional gene silencing are critical for safety and efficacy.
- These issues affect clinical trial sample stratification and the broader adoption of technologies like exosomal mirna analysis and microarray expression analysis, slowing the transition from research to clinical practice.
Exclusive Technavio Analysis on Customer Landscape
The microrna (mirna) market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the microrna (mirna) market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Microrna (mirna) Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, microrna (mirna) market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
BioGenex Laboratories Inc. - Offers a comprehensive suite of miRNA solutions, including qRT-PCR reagent kits, target clones, and precursor expression clones for advanced genomic and proteomic research applications.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- BioGenex Laboratories Inc.
- Bio Rad Laboratories Inc.
- BioVendor LM
- GeneCopoeia Inc.
- Illumina Inc.
- Merck KGaA
- Miltenyi Biotec BV and Co. KG
- NanoString Technologies Inc.
- New England Biolabs Inc.
- OriGene Technologies Inc.
- PerkinElmer US LLC
- QIAGEN N.V.
- Quantabio
- Regulus Therapeutics Inc.
- SeqMatic LLC
- Takara Bio Inc.
- TAmiRNA GmbH
- Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Microrna (mirna) market
- In October, 2024, Resalis Therapeutics received a strategic equity investment from Sanofi to advance RES010, an antisense oligonucleotide designed to inhibit microRNA-22 for treating metabolic diseases.
- In March, 2025, Regulus Therapeutics announced positive topline results from its Phase 1b study of farabursen, a microRNA-targeting medicine, establishing a dose for a future pivotal trial in autosomal dominant polycystic kidney disease.
- In April, 2025, Craif Inc. secured $22 million in a Series C funding round to expand its urinary miRNA-based early cancer detection platform, miSignal, for cancers including pancreatic and ovarian.
- In May, 2025, MiRXES, a Singapore-based diagnostics company, completed its Initial Public Offering on the Hong Kong Stock Exchange, achieving a market capitalization exceeding $1 billion, reflecting strong investor confidence in the miRNA sector.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Microrna (mirna) Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 289 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 22.3% |
| Market growth 2026-2030 | USD 4211.4 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 20.5% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, Russia, China, Japan, India, South Korea, Indonesia, Thailand, Singapore, Australia, Brazil, UAE, Saudi Arabia, South Africa and Turkey |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The Microrna (mirna) Market is characterized by rapid innovation, shifting from pure transcriptomics research to translational medicine applications. This evolution is driven by advancements in mirna expression profiling and non-coding rna analysis, enabling more precise gene expression regulation.
- Key technologies such as next-generation sequencing (ngs) and digital pcr quantification are central to this progress, facilitating breakthroughs in liquid biopsy development and disease signature identification. A significant trend is the dual focus on mirna-based diagnostics and therapeutics, including therapeutic mirna mimics and anti-mirna oligonucleotides (amos).
- Boardroom decisions are increasingly influenced by the potential of the drug discovery pipeline for oncogene regulation and developing tumor suppressor mirna therapies. The adoption of automated molecular pathology systems for small rna library preparation has reduced sample processing time by over 30%, accelerating the biomarker validation process.
- This integration of pathway analysis tools, functional genomics screening, and predictive biomarker development is crucial for advancing clinical assay development and achieving viable commercialization.
What are the Key Data Covered in this Microrna (mirna) Market Research and Growth Report?
-
What is the expected growth of the Microrna (mirna) Market between 2026 and 2030?
-
USD 4.21 billion, at a CAGR of 22.3%
-
-
What segmentation does the market report cover?
-
The report is segmented by Type (Consumables, and Instruments), End-user (Academic and government research, Biotechnology and pharmaceutical companies, and CROs and clinical diagnostic centers), Application (Cancer, Infectious diseases, Cardiovascular diseases, Immunological disorders, and Others) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Increasing incidence of cancer and the imperative for advanced diagnostics and therapeutics, Challenges in standardization and technical reproducibility
-
-
Who are the major players in the Microrna (mirna) Market?
-
BioGenex Laboratories Inc., Bio Rad Laboratories Inc., BioVendor LM, GeneCopoeia Inc., Illumina Inc., Merck KGaA, Miltenyi Biotec BV and Co. KG, NanoString Technologies Inc., New England Biolabs Inc., OriGene Technologies Inc., PerkinElmer US LLC, QIAGEN N.V., Quantabio, Regulus Therapeutics Inc., SeqMatic LLC, Takara Bio Inc., TAmiRNA GmbH and Thermo Fisher Scientific Inc.
-
Market Research Insights
- The Microrna (mirna) Market is shaped by the convergence of advanced diagnostics and therapeutic development, driven by the need for precision oncology applications and better treatment response monitoring. The adoption of multi-cancer early detection (mced) tests combining miRNA with cell-free dna (cfdna) comparison has improved diagnostic accuracy by over 20% in certain use cases.
- Furthermore, the use of miRNA signatures for patient risk stratification in clinical trials has led to a 15% improvement in cohort selection efficiency. The development of companion diagnostic development tools alongside new drugs is another critical dynamic. As research into neurodegenerative disease markers and cardiovascular disease biomarkers intensifies, the market is expanding beyond oncology.
- These advancements collectively underscore a strategic shift toward more personalized and predictive healthcare models.
We can help! Our analysts can customize this microrna (mirna) market research report to meet your requirements.